Sangui Biotech International (Sangui Biotech International) Cash And Cash Equivalents

: $0.01 Mil (As of Mar. 2023)

View and export this data going back to . Start your Free Trial

Sangui Biotech International's quarterly cash and cash equivalents increased from Sep. 2022 ($0.01 Mil) to Dec. 2022 ($0.01 Mil) but then stayed the same from Dec. 2022 ($0.01 Mil) to Mar. 2023 ($0.01 Mil).

Sangui Biotech International's annual cash and cash equivalents increased from Jun. 2020 ($0.02 Mil) to Jun. 2021 ($0.03 Mil) but then stayed the same from Jun. 2021 ($0.03 Mil) to Jun. 2022 ($0.03 Mil).

Sangui Biotech International Cash And Cash Equivalents Historical Data

The historical data trend for Sangui Biotech International's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Cash And Cash Equivalents

0.02

0.03

0.02

0.03

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash And Cash Equivalents																0.07	0.03	0.01	0.01	0.01

Sangui Biotech International Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Sangui Biotech International (OTCPK:SGBI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Sangui Biotech International Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

SBH:Germany

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.

Executives

Hubertus Schmelz	director	NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing	director	ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe	director	NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol	director	ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim	director	ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz	director	SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines